IPI24 (Lymphoma)

The IPI24 (International Prognostic Index evaluated at 24 months) is a prognostic framework for diffuse large B-cell lymphoma (DLBCL) that focuses on outcomes within the first 24 months after diagnosis, a critical period during which the majority of treatment failures and lymphoma-related deaths occur.

Research has demonstrated that patients with DLBCL who achieve complete remission and remain event-free for 24 months after initial diagnosis have subsequent survival rates approaching those of the age- and sex-matched general population. This concept, known as EFS24 (event-free survival at 24 months), has become a landmark milestone in lymphoma management and has transformed how clinicians counsel patients about long-term prognosis.

The IPI24 concept applies the standard International Prognostic Index (IPI) factors — age over 60, elevated LDH, ECOG performance status 2 or greater, Ann Arbor stage III-IV, and 2 or more extranodal sites — but specifically uses them to predict the probability of early treatment failure within the first 24 months. Patients with higher IPI scores have a greater likelihood of relapse or refractory disease during this critical window.

The original IPI was developed in 1993 by the International Non-Hodgkin's Lymphoma Prognostic Factors Project and remains one of the most important tools in oncology. The five factors were identified from analysis of over 2,000 patients and have been validated in numerous subsequent studies. Each point on the IPI reflects an independently significant adverse prognostic factor.

The risk groups are: low risk (0-1 points) with approximately 85% 2-year PFS, low-intermediate risk (2 points) with approximately 65% 2-year PFS, high-intermediate risk (3 points) with approximately 50% 2-year PFS, and high risk (4-5 points) with approximately 40% 2-year PFS. These estimates reflect outcomes in the rituximab era and help identify patients who may benefit from intensified treatment strategies.

Understanding early treatment failure risk is crucial for treatment planning. High-risk patients may be candidates for intensified first-line therapy, early consideration of autologous stem cell transplant consolidation, enrollment in clinical trials of novel agents (e.g., polatuzumab vedotin, CAR-T cell therapy), or more frequent interim response assessment with PET-CT.